UedaSM, KappDS, CheungMK et al.. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol2008;198:218.e1–6.
UedaSMKappDSCheungMK. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol2008;198:218.e1–6.
)| false
DukJM, AaldersJG, FleurenGJ et al.. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix. Obstet Gynecol1989;73:661–668.
DukJMAaldersJGFleurenGJ. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix. Obstet Gynecol1989;73:661–668.
)| false
PatsnerB, OrrJWJr, MannWJJr. Use of serum CA 125 measurement in posttreatment surveillance of early-stage endometrial carcinoma. Am J Obstet Gynecol1990;162:427–429.
PatsnerBOrrJWJrMannWJJr. Use of serum CA 125 measurement in posttreatment surveillance of early-stage endometrial carcinoma. Am J Obstet Gynecol1990;162:427–429.
)| false
RosePG, SommersRM, RealeFR et al.. Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol1994;84:12–16.
RosePGSommersRMRealeFR. Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol1994;84:12–16.
)| false
GimpelsonRJ, RappoldHO. A comparative study between panoramic hysterectomy with directed biopsies and dilatation and curettage: a review of 276 cases. Am J Obstet Gynecol1998;158:489–492.
GimpelsonRJRappoldHO. A comparative study between panoramic hysterectomy with directed biopsies and dilatation and curettage: a review of 276 cases. Am J Obstet Gynecol1998;158:489–492.
)| false
BoronowRC, MorrowCP, CreasmanWT et al.. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol1984;63:825–832.
BoronowRCMorrowCPCreasmanWT. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol1984;63:825–832.
)| false
CowlesTA, MagrinaJF, MastersonBJ et al.. Comparison of clinical and surgical-staging in patients with endometrial carcinoma. Obstet Gynecol1985;66:413–416.
CowlesTAMagrinaJFMastersonBJ. Comparison of clinical and surgical-staging in patients with endometrial carcinoma. Obstet Gynecol1985;66:413–416.
)| false
CreasmanWT, MorrowCP, BundyBN et al.. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study. Cancer1987;60:2035–2041.
CreasmanWTMorrowCPBundyBN. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study. Cancer1987;60:2035–2041.
)| false
BenedetJL, BenderH, JonesHIII et al.. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet2000;70:209–262.
BenedetJLBenderHJonesHIII. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet2000;70:209–262.
)| false
American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol2005;106:413–425.
American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol2005;106:413–425.
)| false
MarianiA, DowdySC, ClibyWA et al.. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol2008;109:11–18.
MarianiADowdySCClibyWA. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol2008;109:11–18.
)| false
ASTEC study groupKitchenerH, SwartAM et al.. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet2009;373:125–136.
ASTEC study groupKitchenerHSwartAM. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet2009;373:125–136.
)| false
Benedetti PaniciP, BasileS, ManeschiF et al.. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst2008;100:1707–1716.
Benedetti PaniciPBasileSManeschiF. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst2008;100:1707–1716.
)| false
CreasmanWT, OdicinoF, MaisonneuveP et al.. Carcinoma of the corpus uteri. FIGO 6th annual report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet2006;95(Suppl 1):S105–143.
CreasmanWTOdicinoFMaisonneuveP. Carcinoma of the corpus uteri. FIGO 6th annual report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet2006;95(Suppl 1):S105–143.
)| false
FishmanDA, RobertsKB, ChambersJT et al.. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma of the endometrium. Gynecol Oncol1996;61:189–196.
FishmanDARobertsKBChambersJT. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma of the endometrium. Gynecol Oncol1996;61:189–196.
)| false
KilgoreLC, PartridgeEE, AlvarezRD et al.. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol1995;56:29–33.
KilgoreLCPartridgeEEAlvarezRD. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol1995;56:29–33.
)| false
CreutzbergCL, van PuttenWL, KoperPC et al.. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet2000;355:1404–1411.
CreutzbergCLvan PuttenWLKoperPC. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet2000;355:1404–1411.
)| false
AaldersJ, AbelerV, KolstadP et al.. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Clinical and histopathologic study of 540 patients. Obstet Gynecol1980;56:419–427.
AaldersJAbelerVKolstadP. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Clinical and histopathologic study of 540 patients. Obstet Gynecol1980;56:419–427.
)| false
KeysHM, RobertsJA, BrunettoVL et al.. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol2004;92:744–751.
KeysHMRobertsJABrunettoVL. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol2004;92:744–751.
)| false
CreutzbergCL, van PuttenWL, Warlam-RodenhuisCC et al.. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol2004;22:1234–1241.
CreutzbergCLvan PuttenWLWarlam-RodenhuisCC. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol2004;22:1234–1241.
)| false
ScholtenAN, van PuttenWL, BeermanH et al.. Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys2005;63:834–838.
ScholtenANvan PuttenWLBeermanH. Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys2005;63:834–838.
)| false
ASTEC/EN.5 Study GroupBlakeP, SwartAM et al.. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet2009;373:137–146.
ASTEC/EN.5 Study GroupBlakePSwartAM. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet2009;373:137–146.
)| false
LeeCM, SzaboA, ShrieveDC et al.. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA2006;295:389–397.
LeeCMSzaboAShrieveDC. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA2006;295:389–397.
)| false
JohnsonN, CornesP. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG2007;114:1313–1320.
JohnsonNCornesP. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG2007;114:1313–1320.
)| false
HogbergT, RosenbergP, KristensenG et al.. A randomized phase-III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991) [abstract]. J Clin Oncol2007;25:Abstract 5503.
HogbergTRosenbergPKristensenG. A randomized phase-III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991) [abstract]. J Clin Oncol2007;25:Abstract 5503.
)| false
MorrowCP, BundyBN, KurmanRJ et al.. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol1991;40:55–65.
MorrowCPBundyBNKurmanRJ. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol1991;40:55–65.
)| false
KadarN, HomesleyHD, MalfetanoJH. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol Oncol1992;46:145–149.
KadarNHomesleyHDMalfetanoJH. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol Oncol1992;46:145–149.
)| false
Owen Mumford. Best Practice Guidelines on the Use of Vaginal Dilators in Women Receiving Pelvic radiotherapy. Available at: http://www.owenmumford.com/en/download.asp?id=59. Accessed March 25, 2009.
Owen Mumford. Best Practice Guidelines on the Use of Vaginal Dilators in Women Receiving Pelvic radiotherapy. Available at: http://www.owenmumford.com/en/download.asp?id=59. Accessed March 25, 2009.
)| false
WalkerJL, PiedmonteM, SpirtosN et al.. Surgical staging of uterine cancer: randomized phase III trial of laparoscopy vs laparotomy—a Gynecologic Oncology Group study (GOG): preliminary results [Abstract]. J Clin Oncol2006;24(Suppl 18):Abstract 5010.
WalkerJLPiedmonteMSpirtosN. Surgical staging of uterine cancer: randomized phase III trial of laparoscopy vs laparotomy—a Gynecologic Oncology Group study (GOG): preliminary results [Abstract]. J Clin Oncol2006;24(Suppl 18):Abstract 5010.
)| false
MalurS, PossoverM, MichelsW, SchneiderA. Laparoscopic-assisted vaginal versus abdominal surgery in patients with endometrial cancer—a prospective randomized trial. Gynecol Oncol2001;80:239–244.
MalurSPossoverMMichelsWSchneiderA. Laparoscopic-assisted vaginal versus abdominal surgery in patients with endometrial cancer—a prospective randomized trial. Gynecol Oncol2001;80:239–244.
)| false
ObermairA, ManolitsasTP, LeungY et al.. Total laparoscopic hysterectomy for endometrial cancer: patterns of recurrence and survival. Gynecol Oncol2004;92:789–793.
ObermairAManolitsasTPLeungY. Total laparoscopic hysterectomy for endometrial cancer: patterns of recurrence and survival. Gynecol Oncol2004;92:789–793.
)| false
BoggessJF, GehrigPA, CantrellL et al.. A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. Am J Obstet Gynecol2008;199:360.e1–9.
BoggessJFGehrigPACantrellL. A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. Am J Obstet Gynecol2008;199:360.e1–9.
)| false
ChadhaM, NanavatiPJ, LiuP et al.. Patterns of failure in endometrial carcinoma stage IB, grade 3 and IC patients treated with postoperative vaginal vault brachytherapy. Gynecol Oncol1999;75:103–107.
ChadhaMNanavatiPJLiuP. Patterns of failure in endometrial carcinoma stage IB, grade 3 and IC patients treated with postoperative vaginal vault brachytherapy. Gynecol Oncol1999;75:103–107.
)| false
ChiDS, BarakatRR, PalayekarMJ et al.. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. Int J Gynecol Cancer2008;18:269–273.
ChiDSBarakatRRPalayekarMJ. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. Int J Gynecol Cancer2008;18:269–273.
)| false
GretzHFIII, EconomosK, HusainA et al.. The practice of surgical staging and its impact on adjuvant treatment recommendations in patients with stage I endometrial carcinoma. Gynecol Oncol1996;61:409–415.
GretzHFIIIEconomosKHusainA. The practice of surgical staging and its impact on adjuvant treatment recommendations in patients with stage I endometrial carcinoma. Gynecol Oncol1996;61:409–415.
)| false
SusumuN, SagaeS, UdagawaY et al.. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol2008;108:226–233.
SusumuNSagaeSUdagawaY. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol2008;108:226–233.
)| false
GreerBE, HambergerAD. Treatment of intraperitoneal metastatic adenocarcinoma of the endometrium by the whole-abdomen moving-strip technique and pelvic boost irradiation. Gynecol Oncol1983;16:365–373.
GreerBEHambergerAD. Treatment of intraperitoneal metastatic adenocarcinoma of the endometrium by the whole-abdomen moving-strip technique and pelvic boost irradiation. Gynecol Oncol1983;16:365–373.
)| false
RandallME, FiliaciVL, MussH et al.. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol2006;24:36–44.
RandallMEFiliaciVLMussH. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol2006;24:36–44.
)| false
HomesleyHD, FiliaciV, GibbonsSK et al.. Randomized phase III trial in advanced endometrial carcinoma of surgery and volume-directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study [abstract]. 39th Annual Meeting of the Society of Gynecologic Oncologists; Tampa, FL; March 9, 2008. Abstract #1. Gynecol Oncol2008;108:S2.
HomesleyHDFiliaciVGibbonsSK. Randomized phase III trial in advanced endometrial carcinoma of surgery and volume-directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study [abstract]. 39th Annual Meeting of the Society of Gynecologic Oncologists; Tampa, FL; March 9, 2008. Abstract #1. Gynecol Oncol2008;108:S2.
)| false
ChapmanJA, DiSaiaPJ, OsannK et al.. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol1996;175:1195–1200.
ChapmanJADiSaiaPJOsannK. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol1996;175:1195–1200.
)| false
GotliebWH, BeinerME, ShalmonB et al.. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol2003;102:718–725.
GotliebWHBeinerMEShalmonB. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol2003;102:718–725.
)| false
RamirezPT, FrumovitzM, BodurkaDC et al.. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol2004;95:133–138.
RamirezPTFrumovitzMBodurkaDC. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol2004;95:133–138.
)| false
PodczaskiE, KaminskiP, GurskiK et al.. Detection and patterns of treatment failure in 300 consecutive cases of “early” endometrial cancer after primary surgery. Gynecol Oncol1992;47:323–327.
PodczaskiEKaminskiPGurskiK. Detection and patterns of treatment failure in 300 consecutive cases of “early” endometrial cancer after primary surgery. Gynecol Oncol1992;47:323–327.
)| false
DowdySC, MarianiA, ClibyWA et al.. Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes. Gynecol Oncol2006;101:280–286.
DowdySCMarianiAClibyWA. Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes. Gynecol Oncol2006;101:280–286.
)| false
TranPT, SuZ, HaraW et al.. Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies. Int J Radiat Oncol Biol Phys2007;69:504–511.
TranPTSuZHaraW. Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies. Int J Radiat Oncol Biol Phys2007;69:504–511.
)| false
KauppilaA. Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. A review of the literature. Acta Oncol1989;28:561–566.
KauppilaA. Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. A review of the literature. Acta Oncol1989;28:561–566.
)| false
ThigpenJT, BradyMF, AlvarezRD et al.. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol1999;17:1736–1744.
ThigpenJTBradyMFAlvarezRD. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol1999;17:1736–1744.
)| false
ThigpenT, BradyMF, HomesleyHD et al.. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol2001;19:364–367.
ThigpenTBradyMFHomesleyHD. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol2001;19:364–367.
)| false
FlemingGF, BrunettoVL, CellaD et al.. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol2004;22:2159–2166.
FlemingGFBrunettoVLCellaD. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol2004;22:2159–2166.
)| false
ReddySP, KudelkaAP, Gonzalez de LeonC et al.. Tumors of the uterine corpus. In: PazdurR, ed. Medical Oncology: A Comprehensive Review. Huntington: PRR; 1996:407–416.
ReddySPKudelkaAPGonzalez de LeonC. Tumors of the uterine corpus. In: PazdurR, ed. Medical Oncology: A Comprehensive Review. Huntington: PRR; 1996:407–416.
)| false
SovakMA, DupontJ, HensleyML et al.. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int J Gynecol Cancer2007;17:197–203.
SovakMADupontJHensleyML. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int J Gynecol Cancer2007;17:197–203.
)| false
SecordAA, HavrileskyLJ, CarneyME et al.. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. Int J Clin Oncol2007;12:31–36.
SecordAAHavrileskyLJCarneyME. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. Int J Clin Oncol2007;12:31–36.
)| false
KellyMG, O’MalleyDM, HuiP et al.. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol2005;98:353–359.
KellyMGO’MalleyDMHuiP. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol2005;98:353–359.
)| false
ThomasMB, MarianiA, ClibyWA et al.. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol Oncol2007;107:186–189.
ThomasMBMarianiAClibyWA. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol Oncol2007;107:186–189.
)| false
GoldbergH, MillerRC, Abdah-BortnyakR et al.. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecol Oncol2008;108:298–305.
GoldbergHMillerRCAbdah-BortnyakR. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecol Oncol2008;108:298–305.
)| false
HamiltonCA, CheungMK, OsannK et al.. The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma. Gynecol Oncol2006;103:679–683.
HamiltonCACheungMKOsannK. The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma. Gynecol Oncol2006;103:679–683.
)| false
MehtaN, YamadaSD, RotmenschJ, MundtAJ. Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys2003;57:1004–1009.
MehtaNYamadaSDRotmenschJMundtAJ. Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys2003;57:1004–1009.
)| false
MurphyKT, RotmenschJ, YamadaSD, MundtAJ. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys2003;55:1272–1276.
MurphyKTRotmenschJYamadaSDMundtAJ. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys2003;55:1272–1276.
)| false
SoodBM, JonesJ, GuptaS et al.. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys2003;57:208–216.
SoodBMJonesJGuptaS. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys2003;57:208–216.
)| false
WolfsonAH, BradyMF, RoceretoT et al.. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol2007;107:177–185.
WolfsonAHBradyMFRoceretoT. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol2007;107:177–185.
)| false
HomesleyHD, FiliaciV, MarkmanM et al.. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group study. J Clin Oncol2007;25:526–531.
HomesleyHDFiliaciVMarkmanM. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group study. J Clin Oncol2007;25:526–531.
)| false
SuttonG, KaudererJ, CarsonLF et al.. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol2005;96:630–634.
SuttonGKaudererJCarsonLF. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol2005;96:630–634.
)| false
ReedNS, MangioniC, MalmströmH et al.. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group study (protocol 55874). Eur J Cancer2008;44:808–818.
ReedNSMangioniCMalmströmH. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group study (protocol 55874). Eur J Cancer2008;44:808–818.
)| false
CallisterM, RamondettaLM, JhingranA et al.. Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys2004;58:786–796.
CallisterMRamondettaLMJhingranA. Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys2004;58:786–796.
)| false
ChiD, MychalczakB, SaigoP et al.. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol1997;65:493–498.
ChiDMychalczakBSaigoP. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol1997;65:493–498.
)| false
KnockeT, WeitmannH, KuceraH et al.. Results of primary and adjuvant radiotherapy in the treatment of mixed Mullerian tumors of the corpus uteri. Gynecol Oncol1999;73:389–395.
KnockeTWeitmannHKuceraH. Results of primary and adjuvant radiotherapy in the treatment of mixed Mullerian tumors of the corpus uteri. Gynecol Oncol1999;73:389–395.
)| false
LarsonB, SilfverswardC, NilssonB et al.. Mixed mullerian tumours of the uterus—prognostic factors: a clinical and histopathologic study of 147 cases. Radiother Oncol1990;17:123–132.
LarsonBSilfverswardCNilssonB. Mixed mullerian tumours of the uterus—prognostic factors: a clinical and histopathologic study of 147 cases. Radiother Oncol1990;17:123–132.
)| false
DusenberyKE, PotishRA, ArgentaPA, JudsonPL. On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus. Am J Clin Oncol2005;28:295–300.
DusenberyKEPotishRAArgentaPAJudsonPL. On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus. Am J Clin Oncol2005;28:295–300.
)| false
NemaniD, MitraN, GuoM, LinL. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol2008;111:82–88.
NemaniDMitraNGuoMLinL. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol2008;111:82–88.
)| false
WolfsonAH, BradyMF, RoceretoT et al.. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol2007;107:177–185.
WolfsonAHBradyMFRoceretoT. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol2007;107:177–185.
)| false
PinkD, LindnerT, MrozekA et al.. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol2006;101:464–469.
PinkDLindnerTMrozekA. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol2006;101:464–469.
)| false
ZivanovicO, IasonosA, LeitaoMM et al.. Stage-specific survival of patients with uterine leiomyosarcoma: a comparison of FIGO and AJCC staging system [abstract]. J Clin Oncol2008;26:Abstract 5554.
ZivanovicOIasonosALeitaoMM. Stage-specific survival of patients with uterine leiomyosarcoma: a comparison of FIGO and AJCC staging system [abstract]. J Clin Oncol2008;26:Abstract 5554.
)| false
GiuntoliRN, MetzingerD, DiMarcoC et al.. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol2003;89:460–469.
GiuntoliRNMetzingerDDiMarcoC. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol2003;89:460–469.
)| false
HensleyML, MakiR, VenkatramanE et al.. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol2002;20:2824–2831.
HensleyMLMakiRVenkatramanE. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol2002;20:2824–2831.
)| false
HensleyML, BlessingJA, MannelR, RosePG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol2008;109:329–334.
HensleyMLBlessingJAMannelRRosePG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol2008;109:329–334.
)| false
LookKY, SandlerA, BlessingJA et al.. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study. Gynecol Oncol2004;92:644–647.
LookKYSandlerABlessingJA. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study. Gynecol Oncol2004;92:644–647.
)| false
JudsonI, RadfordJA, HarrisM et al.. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer2001;37:870–877.
JudsonIRadfordJAHarrisM. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer2001;37:870–877.
)| false
SuttonG, BlessingJ, HanjaniP et al.. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol2005;96:749–752.
SuttonGBlessingJHanjaniP. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol2005;96:749–752.
)| false
GallupDG, BlessingJA, AndersenW et al.. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol2003;89:48–51.
GallupDGBlessingJAAndersenW. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol2003;89:48–51.
)| false
